Successful Treatment of Aggressive HIV-associated Non-Hodgkin's Lymphoma with Combination Chemotherapy, Biotherapy with Rituximab and HAART: Presentation of a Therapeutic Option
Authors:
- 1 January 2003
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 44 (2) , 349-351
Abstract
The incidence of non-Hodgkin's lymphoma (NHL) in individuals infected with human immunodeficiency virus (HIV) is more than 60 times higher than in matched controls. In the vast majority of cases aggressive pathological subtypes and advanced stages prevail, extranodal sites are involved and systemic symptoms are present. The prognosis of HIV-NHL remains poor and the optimal therapeutic approach has yet to be defined. We report a 48-year-old Ethiopian woman with advanced-stage HIV infection, who developed diffuse large cell, immunoblastic type B-cell NHL and was treated with a modified CHOP-like chemotherapy combined with Rituximab and supported with growth factor. Highly active antiretroviral therapy (HAART) and opportunistic infections prophylaxis were administered concomitantly. The patient completed 6 cycles of therapy and currently, 76 weeks after diagnosis, is in complete clinical remission. Despite the fact that there was a transient decrease in the CD4-positive cell number and a 1.5 log increase in plasma viral load there were no opportunistic infections, nor was life-threatening toxicity seen. Rituximab seems a well-tolerable and advantageous adjunct to chemotherapy and HAART in the treatment of aggressive HIV-associated NHL and should be investigated in large trials in the future.Keywords
This publication has 7 references indexed in Scilit:
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Anti-CD20 Monoclonal Antibody Treatment of Human Herpesvirus 8-Associated, Body Cavity-Based Lymphoma with an Unusual Phenotype in a Human Immunodeficiency Virus-Negative PatientClinical and Diagnostic Laboratory Immunology, 2001
- Successful treatment with rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low‐grade non‐Hodgkin's lymphomaAmerican Journal of Hematology, 2001
- CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s MacroglobulinemiaJournal of Immunotherapy, 2001
- Monotherapy with Rituximab Induces Rapid Remission of Recurrent Cold Agglutinin-Mediated Hemolytic Anemia in a Patient with Indolent Lympho-Plasmacytic LymphomaLeukemia & Lymphoma, 2001
- Evolving characteristics of AIDS-related lymphomaBlood, 2000
- Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.British Journal of Haematology, 1999